BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On June 14, 2017, the Board of Directors of Bioanalytical
Systems, Inc. (the Company) unanimously elected Gregory C.
Davis, Ph.D. as an independent, Class III director. Dr. Davis
term will expire at the 2018 annual meeting of shareholders. The
Board of Directors has not determined the committees of the Board
of Directors to which Dr. Davis will be named. The Company will
disclose that information once determined.

As a director of the Company, Dr. Davis will receive compensation
as a non-employee director in accordance with the Companys
non-employee director compensation practices described in the
Companys Proxy Statement on Schedule 14A filed with the
Securities and Exchange Commission on January 30, 2017. This
compensation generally consists of cash payments (annual cash
retainers and board and committee meeting fees) and such stock
option awards as may be granted from time to time.

A copy of the press release announcing the election of Dr. Davis
is attached as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

BIOANALYTICAL SYSTEMS INC Exhibit
EX-99.1 2 v469186_ex99-1.htm EXHIBIT 99.1    Exhibit 99.1           FOR MORE INFORMATION: Company Contact:    Jill Blumhoff  Chief Financial Officer &   Vice President of Finance    Phone:  765.497.8381    [email protected]       BASi Names Dr. Gregory C. Davis to Board of Directors     WEST LAFAYETTE,…
To view the full exhibit click here
About BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI)

Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs.